RSs for patients with BLCA were calculated according to the formula: 0.0076 × NFIA-AS2 expression level) + (0.1409 × NR2F1-AS1 expression level) + (0.0011 × MIR99AHG expression level) + (−0.0678 × TMEM147-AS1 expression level) + (0.1822 × RAP2C-AS1) (Figure 3C). This evidence concerns the gene RAP2C and bladder transitional cell carcinoma.